Since LINC00152 silencing decreased the expression of MDRP1 as well as GSTP1, it is proposed as a potential novel therapeutic target related to downregulation of GSTP1 expression and ovarian cancer chemosensitising [67]. Here, GSTP1 is linked to ovarian cancer.